Management of COVID‐19‐associated coagulopathy in persons with haemophilia
dc.contributor.author | Pipe, Steven W. | |
dc.contributor.author | Kaczmarek, Radoslaw | |
dc.contributor.author | Srivastava, Alok | |
dc.contributor.author | Pierce, Glenn F. | |
dc.contributor.author | Makris, Mike | |
dc.contributor.author | Hermans, Cedric | |
dc.date.accessioned | 2021-03-02T21:44:53Z | |
dc.date.available | 2022-02-02 16:44:52 | en |
dc.date.available | 2021-03-02T21:44:53Z | |
dc.date.issued | 2021-01 | |
dc.identifier.citation | Pipe, Steven W.; Kaczmarek, Radoslaw; Srivastava, Alok; Pierce, Glenn F.; Makris, Mike; Hermans, Cedric (2021). "Management of COVID‐19‐associated coagulopathy in persons with haemophilia." Haemophilia (1): 41-48. | |
dc.identifier.issn | 1351-8216 | |
dc.identifier.issn | 1365-2516 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/166388 | |
dc.description.abstract | IntroductionThe SARS‐CoV‐2 coronavirus‐induced infection (COVID‐19) can be associated with a coagulopathy mainly responsible for pulmonary microvasculature thrombosis and systemic thromboembolic manifestations. The pathophysiology and management of the COVID‐19 coagulopathy are likely more complex in patients with inherited bleeding diseases such as haemophilia. These individuals might indeed present with both bleeding and thrombotic complications and require simultaneous antithrombotic and haemostatic treatments.ObjectiveWe propose practical guidance for the diagnosis and management of COVID‐19 coagulopathy in persons with haemophilia.ResultsContinuation of regular haemostatic treatment is recommended for ambulatory patients. For patients requiring hospital admission and on replacement therapy with factors VIII or IX concentrates, prophylaxis with concentrates should be intensified according to the risk of bleeding complications and associated with prophylactic doses of LMWH. For patients on nonreplacement therapy, emicizumab should be continued and possibly combined with factor VIII and prophylactic doses of LMWH depending on the risk of bleeding and thrombosis. Dose escalation of LMWH tailored to the risk of thrombosis can be employed but not supported by evidence.ConclusionsThese practical recommendations are based on the current literature on COVID‐19 with its impact on haemostasis, indications and modalities for thromboprophylaxis mainly in nonhaemophilic patients and how that is likely to affect persons with haemophilia in different circumstances. They will need to be tailored to each patient’s clinical status and validated in future studies. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | emicizumab | |
dc.subject.other | haemophilia | |
dc.subject.other | thromboprophylaxis | |
dc.subject.other | coagulopathy | |
dc.subject.other | COVID‐19 | |
dc.subject.other | clotting factor concentrates | |
dc.title | Management of COVID‐19‐associated coagulopathy in persons with haemophilia | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/166388/1/hae14191.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/166388/2/hae14191_am.pdf | |
dc.identifier.doi | 10.1111/hae.14191 | |
dc.identifier.source | Haemophilia | |
dc.identifier.citedreference | Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020; 18 ( 5 ): 1023 – 1026. | |
dc.identifier.citedreference | Harzallah I, Debliquis A, Drenou B. Frequency of lupus anticoagulant in Covid‐19 patients. J Thromb Haemost. 2020; 18 ( 10 ): 2778 – 2778. | |
dc.identifier.citedreference | Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with covid‐19. N Engl J Med. 2020; 383 ( 3 ): 288 – 290. | |
dc.identifier.citedreference | Weyand AC, Dorfman AL, Shavit JA, Pipe SW. Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra‐atrial thrombosis in severe haemophilia with an inhibitor. Haemophilia. 2019; 25 ( 3 ): e203 – e205. | |
dc.identifier.citedreference | Levi M, Hunt BJ. Thrombosis and coagulopathy in COVID‐19: an illustrated review. Res Pract Thromb Haemost. 2020; 4: 744 – 751. | |
dc.identifier.citedreference | Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017; 377 ( 9 ): 819 – 828. | |
dc.identifier.citedreference | Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019; 134 ( 22 ): 1973 – 1982. | |
dc.identifier.citedreference | Chowdary P. Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab. Drugs. 2018; 78 ( 9 ): 881 – 890. | |
dc.identifier.citedreference | Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R. A molecular revolution in the treatment of hemophilia. Mol Ther. 2020; 28 ( 4 ): 997 – 1015. | |
dc.identifier.citedreference | Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382 ( 8 ): 727 – 733. | |
dc.identifier.citedreference | Hermans C, Weill A, Pierce GF. The COVID‐19 pandemic: new global challenges for the haemophilia community. Haemophilia. 2020; 26 ( 3 ): 371 – 372. | |
dc.identifier.citedreference | Cui D, Zhang A, Liu A, Hu Q. Clinical findings in a patient with haemophilia A affected by COVID‐19. Haemophilia. 2020; 26 ( 4 ): e214 – e216. | |
dc.identifier.citedreference | Hermans C, Lambert C, Sogorb A, Wittebole X, Belkhir L, Yombi JC. In‐hospital management of persons with haemophilia and COVID‐19: practical guidance. Haemophilia. 2020; 26 ( 5 ): 768 – 772. | |
dc.identifier.citedreference | Coppola A, Tagliaferri A, Rivolta GF, Quintavalle G, Franchini M. Confronting COVID‐19: issues in hemophilia and congenital bleeding disorders. Semin Thromb Hemost. 2020; 46 ( 7 ): 819 – 822. | |
dc.identifier.citedreference | Rivas‐Pollmar MI, Alvarez‐Roman MT, Butta‐Coll NV, Martin SM, Garcia‐Barcenilla S, Jimenez‐Yuste V. Thromboprophylaxis in a patient with COVID‐19 and severe hemophilia A on emicizumab prophylaxis. J Thromb Haemost. 2020; 18 ( 9 ): 2202 – 2204. | |
dc.identifier.citedreference | Zhang A, Liu W, Poon MC, et al. Management of haemophilia patients in the COVID‐19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China. Haemophilia. 2020. | |
dc.identifier.citedreference | Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost. 2020; 46 ( 07 ): 772 – 776. | |
dc.identifier.citedreference | Leisman DE, Deutschman CS, Legrand M. Facing COVID‐19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020; 46: 1105 – 1108. | |
dc.identifier.citedreference | Becker RC. COVID‐19 update: Covid‐19‐associated coagulopathy. J Thromb Thrombolysis. 2020; 50 ( 1 ): 54 – 67. | |
dc.identifier.citedreference | Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID‐19. Lancet Haematol. 2020; 7 ( 6 ): e438 – e440. | |
dc.identifier.citedreference | Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18 ( 5 ): 1094 – 1099. | |
dc.identifier.citedreference | Fogarty H, Townsend L, Ni CC, et al. COVID‐19 coagulopathy in caucasian patients. Br J Haematol. 2020; 189 ( 6 ): 1044 – 1049. | |
dc.identifier.citedreference | Thachil J, Srivastava A. SARS‐2 coronavirus‐associated hemostatic lung abnormality in COVID‐19: is it pulmonary thrombosis or pulmonary embolism? Semin Thromb Hemost. 2020; 46 ( 07 ): 777 – 780. | |
dc.identifier.citedreference | Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid‐19. N Engl J Med. 2020; 383: 120 – 128. | |
dc.identifier.citedreference | Lang M, Som A, Mendoza DP, et al. Hypoxaemia related to COVID‐19: vascular and perfusion abnormalities on dual‐energy CT. Lancet Infect Dis. 2020. | |
dc.identifier.citedreference | Libby P, Luscher T. COVID‐19 is, in the end, an endothelial disease. Eur Heart J. 2020; 41 ( 32 ): 3038 – 3044. | |
dc.identifier.citedreference | Miesbach W. Pathological role of angiotensin II in severe COVID‐19. TH Open. 2020; 4 ( 2 ): e138 – e144. | |
dc.identifier.citedreference | Connors JM, Levy JH. COVID‐19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135 ( 23 ): 2033 – 2040. | |
dc.identifier.citedreference | Bikdeli B, Madhavan MV, Jimenez D, et al. COVID‐19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow‐up. J Am Coll Cardiol. 2020; 75 ( 23 ): 2950 – 2973. | |
dc.identifier.citedreference | Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 ( 4 ): 844 – 847. | |
dc.identifier.citedreference | Al‐Samkari H, Karp Leaf RS, Dzik WH, et al. COVID‐19 and coagulation: bleeding and thrombotic manifestations of SARS‐CoV‐2 infection. Blood. 2020; 136 ( 4 ): 489 – 500. | |
dc.identifier.citedreference | Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 ( 6 ): 1421 – 1424. | |
dc.identifier.citedreference | Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID‐19. Thromb Res. 2020; 191: 145 – 147. | |
dc.identifier.citedreference | Shi C, Wang C, Wang H, et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID‐19 patients: a retrospective cohort study. Clin Transl Sci. 2020; 0: 1 – 9. | |
dc.identifier.citedreference | Thachil J, Juffermans NP, Ranucci M, et al. ISTH DIC subcommittee communication on anticoagulation in COVID‐19. J Thromb Haemost. 2020; 18 ( 9 ): 2138 – 2144. | |
dc.identifier.citedreference | Oudkerk M, Buller HR, Kuijpers D, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID‐19: report of the national institute for public health of the Netherlands. Radiology. 2020;201629. 297 ( 01 ): e216 – e222. | |
dc.identifier.citedreference | https://www.wsh.nhs.uk/covid‐staff‐zone/Guidelines‐SOPs‐clinical‐info/Docs/Clinical‐guideline/CG10393‐COVID‐Thromboprophylaxis‐and‐Anticoagulation‐in‐COVID‐19‐infections.pdf. 2020. | |
dc.identifier.citedreference | Coagulopathy of COVID‐19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care. https://www.clinicaltrials.gov/ct2/show/NCT04362085. 2020; 9. | |
dc.identifier.citedreference | Xu H, Zhong R, Wang K, et al. Diagnostic values of inflammatory and angiogenic factors for acute joint bleeding in patients with severe hemophilia A. Clin Appl Thromb Hemost. 2020; 26: 1076029619892683: 1 – 6. | |
dc.identifier.citedreference | Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia. 2007; 13 ( 3 ): 244 – 248. | |
dc.identifier.citedreference | Adamkewicz JI, Chen DC, Paz‐Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor viii cofactor function, on coagulation assays. Thromb Haemost. 2019; 119 ( 7 ): 1084 – 1093. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.